online game zombie
online game zombie
OpenAI CEO Sam Altman has pledged a personal donation of $1 million to President-elect Donald Trump’s inaugural fund. This is just after Meta and Amazon also made similar commitments, marking a new dynamic in the relationship between the tech industry and the incoming administration. A spokesperson for OpenAI confirmed the donation on Friday, 13 December. Altman said he is backing the vision of President Trump stating, “President Trump will lead our country into the age of AI, and I am eager to support his efforts to ensure America stays ahead.” Meta, which owns Facebook and Instagram, had previously issued a statement pledging a $1 million donation itself. Amazon confirmed its pledge and announced plans to provide an in-kind contribution as well by live-streaming Trump’s inauguration on Prime Video, an offering estimated at another $1 million. Musk And Altman: An Escalating Feud While Altman is optimistic on Trump, he also told of his lawsuit against another rival, Elon Musk, the world’s richest individual. Trump tapped Musk for co-leading a newly constituted Department of Government Efficiency along with entrepreneur Vivek Ramaswamy. An advisory body meant to ensure that wasteful spending decreases and regulations are eased up in order to streamline governmental operations. Despite the professional differences, downplaying Musk’s growing influence in the administration, he said, ‘I am not that worried about Elon’s role. There’s enough room for multiple voices in shaping America’s future.'” Intersection Of Tech And Politics The tech industry’s support for Trump’s inaugural fund speaks to a larger effort to align with the new administration’s priorities. Altman’s donation, along with those from Meta and Amazon, reflects the sector’s recognition of artificial intelligence and technology as central to future economic growth and global competitiveness. With these high-profile contributions, the inauguration is shaping to be a landmark moment in tech’s influence in politics. Altman’s statement indicates his desire to partner with Trump’s administration for the U.S. to continue leading in AI innovations. ALSO READ | Deportation Looms For 18,000 Indians As Trump Tightens Border Laws
Jim Harbaugh, Justin Herbert and the Los Angeles Chargers celebrated in the locker room Saturday after they wrapped up a playoff spot with a 40-7 victory over the New England Patriots . But even as they realized one goal by making the postseason, Harbaugh tried to keep things focused on the road ahead by stressing: “There's more to do.” The Chargers (10-6) go into the regular-season finale at Las Vegas knowing they will be at least the AFC's sixth seed and avoid a trip to Buffalo for the wild-card round. Los Angeles currently is in line to face Baltimore in a Harbaugh Bowl rematch, but it has an outside shot at the fifth seed and a trip to Houston if Cincinnati beats Pittsburgh next weekend. While Harbaugh credited his players for the turnaround from five wins last year to double-digit victories this season, Herbert gave most of it to Harbaugh and first-year general manager Joe Hortiz. “They have done such a great job of getting the right guys here. You look in the locker room and everybody plays for each other,” Herbert said. “(Harbaugh's) a competitor, and he wants to win no matter what it is. It definitely shows, and it’s the way everyone fights for him, wants to play for him, and respects him.” Harbaugh is the fifth coach in NFL history to win at least 10 games in his first season with two teams. He is also the eighth to make the playoffs in his first season with two teams. “Very little to do with me. If it goes right, then it’s our players. They’re doing a great job. It’s gone bad a couple times. That’s on me,” he said. “I’ve been drinking the Kool-Aid here from day one, I can’t give enough credit to Derwin James, Justin Herbert, and those two in particular. And Khalil Mack and Rashawn Slater. I mean, stalwarts. Brad Bozeman has come in. He’s been a stalwart. There’s a bunch. There’s probably, like — I counted it up early. There was maybe 15, 15 stalwarts that we had, and it’s grown since then.” Even though the Chargers are 3-5 against teams with winning records at the time they've played them, they are 7-1 against teams that were at or under .500. Four of those wins against opponents with losing records have come by at least 17 points, the first time since 2017 the Bolts have won that many games by as big a margin. Since halftime of their Dec. 19 game against Denver, the Chargers have outscored the Broncos and Patriots 61-13 over six quarters. “That’s the type of football we want to be playing in December, January, and hopefully on. That’s the type of football you want to be playing, especially in these big games like that. It was really good to see,” Herbert said. What’s working Offensive coordinator Greg Roman has said throughout the season it's tough to use the full playbook when the Chargers have short drives. They came into Saturday's game ranked 26th with only 23 possessions of at least 10 plays, but they had four against the Patriots, leading to three touchdowns and a field goal. It was the first time since Week 10 last season against Detroit they have had at least four drives of double-digit plays. What needs help Kickoff return coverage. The Chargers have allowed nine kick returns of at least 30 yards, eighth most in the league. New England's Alex Erickson had three returns for 90 yards, including 34 and 31 yards. Stock up RB J.K. Dobbins was activated off injured reserve and provided a boost to the offense with 76 yards on 19 carries and a touchdown. Dobbins, who missed four games due to a knee injury, has set career highs in scrimmage yards (983) and rushing yards (842) in his first season with the Chargers. Stock down WR D.J. Chark was targeted four times but didn't have a catch. Chark was signed during the offseason to provide experience and speed to a young receiver group. However, he missed the first half of the season with a hip injury and has played sparingly since his return. He has three receptions on the season. Injuries Three starters — RB Gus Edwards (ankle), LB Denzel Perryman (groin) and OG Trey Pipkins (hip) — were inactive. WR Joshua Palmer (heel) and DB Elijah Molden (shin) were injured in the second half. Key numbers 77 and 1,054 — Receptions and receiving yards by Ladd McConkey, both records for a Chargers rookie. 5 — Consecutive seasons by Herbert with at least 3,000 passing yards and 20 touchdown passes, tied with Peyton Manning and Russell Wilson for the most to start a career. 2 — Sacks by Derwin James Jr. against the Patriots, the first time in the safety's seven-year career he has had multiple sacks in a game. What’s next The Chargers go for their first season sweep of the Raiders since 2018 in the regular-season finale. ___ AP NFL: https://apnews.com/hub/NFL Joe Reedy, The Associated PressU.S. Clinical Nutrition Market Poised for Tremendous Growth from 2024 to 2032 12-20-2024 06:55 PM CET | Health & Medicine Press release from: Cognate Insights U.S. Clinical Nutrition Market Latest Market Overview The U.S. clinical nutrition market is poised for significant growth, with an estimated market size of USD 19.5 billion in 2024 and a projected compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This growth is driven by increasing incidences of chronic diseases, the rising aging population, and growing awareness of the importance of proper nutrition in disease management and recovery. Clinical nutrition, which encompasses enteral and parenteral nutrition, is seeing widespread adoption across hospitals, healthcare facilities, and home care settings, as it plays a critical role in improving the health and well-being of patients with medical conditions. The U.S. Clinical Nutrition Market has experienced steady growth in recent years and is expected to continue expanding at a strong pace from 2024 to 2032. This analysis offers a comprehensive overview, providing valuable insights into key trends and developments within the U.S. Clinical Nutrition industry. These findings equip business leaders with the necessary knowledge to devise more effective strategies and enhance profitability. Furthermore, the report serves as a useful resource for new and emerging businesses, helping them make informed decisions as they navigate the market and seek growth opportunities. Major Players of U.S. Clinical Nutrition Market are: Nestlé Health Science (Switzerland) - Revenue: USD 15.1 billion Abbott Laboratories (U.S.) - Revenue: USD 43.1 billion Danone Nutricia (France) - Revenue: USD 4.8 billion B. Braun Melsungen AG (Germany) - Revenue: USD 7.9 billion Fresenius Kabi AG (Germany) - Revenue: USD 8.6 billion Get Latest PDF Sample Report @ https://www.cognateinsights.com/request-sample/us-clinical-nutrition-market-research Our Report covers global as well as regional markets and provides an in-depth analysis of the overall growth prospects of the market. Global market trend analysis including historical data, estimates to 2024, and compound annual growth rate (CAGR) forecast to 2032 is given based on qualitative and quantitative analysis of the market segments involving economic and non-economic factors. Furthermore, it reveals the comprehensive competitive landscape of the global market, the current and future market prospects of the industry, and the growth opportunities and drivers as well as challenges and constraints in emerging and emerging markets. Global U.S. Clinical Nutrition Market Landscape and Future Pathways: North America: United States Canada Europe: Germany France U.K. Italy Russia Asia-Pacific: China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia Latin America: Mexico Brazil Argentina Korea Colombia Middle East & Africa: Turkey Saudi Arabia UAE Korea Speak to Our Analyst for A Discussion on The Above Findings, And Ask for A Discount on The Report @ https://www.cognateinsights.com/check-discount/us-clinical-nutrition-market-research Key drivers and challenges influencing the U.S. Clinical Nutrition market: Regional Analysis: The report involves examining the U.S. Clinical Nutrition market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets. Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the U.S. Clinical Nutrition market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends. Company Analysis: Report covers individual U.S. Clinical Nutrition manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies. Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards U.S. Clinical Nutrition This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application. Technology Analysis: Report covers specific technologies relevant to U.S. Clinical Nutrition. It assesses the current state, advancements, and potential future developments in U.S. Clinical Nutrition areas. Reason to Buy this Report: -Analysis of the impact of technological advancements on the market and the emerging trends shaping the industry in the coming years. -Examination of the regulatory and policy changes affecting the market and the implications of these changes for market participants. -Overview of the competitive landscape in the U.S. Clinical Nutrition market, including profiles of the key players, their market share, and strategies for growth. -Identification of the major challenges facing the market, such as supply chain disruptions, environmental concerns, and changing consumer preferences, and analysis of how these challenges will affect market growth. -Evaluation of the potential of new products and applications in the market, and analysis of the investment opportunities for market participants. For In-Depth Competitive Analysis - Purchase this Report now at @ https://www.cognateinsights.com/purchase-report/us-clinical-nutrition-market-research Contact Us: Cognate Insights Web: www.cognateinsights.com Email: info@cognateinsights.com Phone: +91 8424946476 About Us: We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy. This release was published on openPR.X-Bow to Receive Additional Funding for Expansion of DoD Contract for Hypersonic Solid Rocket Motor Development
Analyst Expectations For Nasdaq's FutureCubs acquire All-Star outfielder Kyle Tucker in trade with the Astros
NoneWalmart finally restocked the $249 Ninja SLUSHi and fans are grabbing it ‘frost’ and furiously
Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Aries : Today’s energy is more realistic about your career goals. Although dreaming big can help to motivate people, reaching for the stars needs some realistic view. Take stock of the available assets and find out how to optimise them. It is time to revisit your values—what are the areas in which you really should be putting your money to advance your career? Have faith in your dream, but do not neglect to rationalise it! Taurus : Believe in your words; what you say can get to the right people and create opportunities for you. Whether it is in an official PowerPoint presentation, a conversation, or a daring proposition, your message will be heard by those who need to hear it. This is the moment you are about to reach the turning point in your career advancement. This is a day to have faith in yourself and your process. Be ready to receive advice. Gemini : The stars are encouraging you to engage in work activities that would initially appear to be difficult. Approach them without fear since they unlock the door to demonstrating your leadership skills. Whether it is a challenging assignment, a conflictive discussion, or a chance to introduce your proposals, stepping up will make you a person people turn to. Your problem-solving and creativity shall draw the attention of your superiors. Cancer : If you’ve been thinking of making a leap in your career – whether it’s a switch of roles, a new project, or entering into a leadership position, this is the right time to go for it. The energy is not completely stable but not completely unpredictable, which is just enough to create a sustainable foundation for success. Go with your gut and keep your mind and ears open to anything that you come across. Leo : Today, you might feel like being in the middle of a hurricane at work, struggling with a conflict that doesn’t seem solvable. Your strong opinions, though, could have exacerbated this issue. This is why know when to take a pause and get back. Just take time and try to assess the situation with a stable mind. Use your innate leadership qualities to avoid turning it into a confrontation. This will leave a good impression before your superiors. Virgo : It is now time for the fruits of your labour to show, and they are not disappointing. As an employee, you are likely to experience progress in your career. A chance to be noticed may come, so do not sit on your laurels and hide your talent and creativity. Today could be a good day to seal lucrative business deals or other gains. You are confident; others will see you are determined and have a vision. Libra : A procrastination habit or the ability to forget some important tasks may bother you today, and you may have unnecessary stress. Ensure you are conscious of the amount of time you spend on the activities. This is a reminder to meet all due dates and targets. Empty your list of things to do one at a time to reduce stress at the last minute. Business owners must look at the fine print in contracts or agreements. Scorpio : During the course of your work day, the cosmic energy will help you embrace the notion of taking the road less travelled. New concepts and progressive approaches will be appreciated and will surely bring changes in your career. Whether you are addressing a group of colleagues to pitch a new concept or are challenged in a new situation, you can show your creativity. Look for a job not in your interest area or field; you might find something interesting. Sagittarius : Relationships will be important in achieving your objectives, so avoid creating barriers. You should be careful with what you say because your words have power. For job seekers, networking and polite follow-ups will be advantageous. For those employed, remember the way you present your ideas, especially during meetings or discussions. Being thoughtful will get you respect. End the day by thanking a coworker who has stood by you. Capricorn : Any sort of change or investment should not be done without looking at all aspects. The stars want you to take time, think it over, and then act with care. For job seekers, clean up your resume and cover letter and know all that can be known about a job before you apply for it. Employees should avoid making hasty decisions at the workplace and instead work on improving existing tasks. Aquarius : The stars want you to concentrate on your objectives with passion and zeal. Success is just around the corner if you focus on the proper utilization of your energy. Ensure that self-confidence level is high. Therefore, it is the right day to take risks—submit an application for that desired position or arrange an interview. For those employed, taking calculated risks, such as leading a project or offering new ideas to management, will work to your advantage. Pisces : It is time to reskill or look for positions that require flexibility and an international perspective. Approach each opportunity without preconceived notions, as this will be your most powerful asset. You have to be ready for new challenges, as they promise breakthroughs. Trust your capacity for change, and take this opportunity to learn how to do it better. Leave your comfort zone and open your arms to opportunities. ---------------------- Neeraj Dhankher (Vedic Astrologer, Founder - Astro Zindagi) Email: info@astrozindagi.in , neeraj@astrozindagi.in Url: www.astrozindagi.in Contact: Noida: +919910094779Shares of Trump Media and Technology Group slid in midday trading on Friday after US President-elect Donald Trump transferred all his shares into a revocable trust, according to a regulatory filing. Mr Trump transferred all of his nearly 115 million shares — worth around four billion dollars (£3.2 billion) on paper — in the parent company of social networking site Truth Social as a “bona fide gift” to the Donald J Trump Revocable Trust, the Securities and Exchange Commission filing on on Thursday said. Mr Trump’s shares amount to more than half of the company’s stock. It is not clear why Mr Trump transferred the stock. Donald Trump Jr is the sole trustee and has sole voting and investment power over all securities owned by the trust. Trump Media shares were down about 2% at midday, to 34.68 dollars each. At one point on Friday, they were down around 6%. Trump Media shares have been volatile since the company began trading in March. They reached intraday highs close to 80 dollars (£63.70) on the first day of trading, then slumped to all-time lows in September when Mr Trump and other insiders were finally allowed to sell shares after standard lock-up agreements expired. Mr Trump has not sold any shares in the company. The company’s stock price has fluctuated wildly on news — good and bad — related to Mr Trump. They tumbled after Mr Trump’s conviction in a hush money trial in May, then surged after the first assassination attempt on him in July. They surged again after he won re-election in November, even as the company reported a 19.2 million-dollar (£15.29 million) third-quarter loss. Mr Trump created Trump Media after he was banned from Twitter and Facebook following the January 6 2021 Capitol riot.
Jim Harbaugh and Chargers focused on accomplishing more after wrapping up playoff berthNone
